NCT05444257

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2022-11-08Est. Completion: 2026-10-30

Enrollment target: 822 participants

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner University of Arizona Medical Center, Tucson, Arizona, United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Miller Children's Hospital / Long Beach Memorial, Long Beach, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
Kaiser Permanente, Oakland, California, United States
University of California Davis Medical Center, Sacramento, California, United States
University of California San Francisco, Lung Transplant Program, San Francisco, California, United States
Children's Hospital of Colorado, Aurora, Colorado, United States
National Jewish Health, Denver, Colorado, United States
University of Florida, Shands Hospital, Gainesville, Florida, United States
Joe DiMaggio Cystic Fibrosis & Pulmonary Center, Hollywood, Florida, United States
University of Miami Miller School of Medicine, Miami, Florida, United States
Central Florida Pulmonary Group,PA, Orlando, Florida, United States
Nemours Children's Specialty Care, Pensacola, Florida, United States
Johns Hopkins All Children's Hospital Outpatient Care Center, St. Petersburg, Florida, United States
The Emory Clinic at Chantilly, Atlanta, Georgia, United States
Augusta University, Augusta, Georgia, United States
St. Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
Indiana University, Indianapolis, Indiana, United States
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
University of Kentucky, Lexington, Kentucky, United States

Other microbiome trials you might be interested in

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delPhase 3Recruiting

Cystic Fibrosis

This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic …

Innsbruck, AustriaEst. completion Apr 6, 2027

View Trial →

Role of Genetic Factors in the Development of Lung DiseaseRecruiting

Cystic FibrosisPulmonary FibrosisTuberous SclerosisAsthmaPulmonary Sarcoidosis

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved …

Bethesda, United States

View Trial →

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.